Drug Profile
Dasiglucagon - Zealand Pharma/Novo Nordisk
Alternative Names: HypoPal rescue pen; ZEGALOGUE; Zegalogue®; ZP 4207; ZP-GA-1Latest Information Update: 29 Feb 2024
Price :
$50
*
At a glance
- Originator Zealand Pharma
- Developer Beta Bionics; Zealand Pharma
- Class Antihyperglycaemics; Antihypoglycaemics; Peptides
- Mechanism of Action Glucagon receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Congenital hyperinsulinism
Highest Development Phases
- Marketed Hypoglycaemia
- Preregistration Congenital hyperinsulinism
- Phase II/III Type 1 diabetes mellitus
Most Recent Events
- 27 Feb 2024 Zealand Pharma announces intention to resubmit NDA to USFDA for hypoglycemia in pediatric patients in fist half of 2024
- 01 Sep 2023 Planned Prescription Drug User Fee Act (PDUFA) date for Congenital-hyperinsulinism (In infants, In neonates) in USA (SC) is 2023-12-30
- 31 Aug 2023 Dasiglucagon receives priority review status for Congenital hyperinsulinism (In Infants, In Neonates) in USA